Skip to main content

Table 2 Prevalence and anatomic site of gonorrhea (GC) and chlamydia (CT) infections at baseline and follow-up visits

From: Expedited Partner Therapy (EPT) increases the frequency of partner notification among MSM in Lima, Peru: a pilot randomized controlled trial

Anatomic site of infection Control arm EPT arm
Baseline
(N = 84)a
Follow-up
(N = 72)
Baseline
(N = 89)
Follow-up
(N = 83)
Any site/any pathogen n = 79b
94.0%
(86.8–97.4%)
n = 2c
2.8%
(0.8–9.6%)
n = 81
91.0%
(83.2–95.4%)
n = 2
2.4%
(0.7–8.4%)
Urethral CT n = 4
5.1%
(2.0–12.3%)
  n = 10
11.2%
(6.2–19.5%)
 
Urethral GC n = 6
7.1%
(3.3–14.7%)
  n = 11
12.4%
(7.0–20.8%)
 
Urethral CT and GC n = 2
2.4%
(0.6–8.3%)
  n = 5
6.2%
(2.7–13.6%)
 
Rectal CT n = 24
28.6%
(20.0–39.0%)
n = 2
2.8%
(0.8–9.6%)
n = 32
36.0%
(26.8–46.3%)
n = 1
1.2%
(0.2–6.5%)
Rectal GC n = 12
14.3%
(8.4–23.3%)
  n = 4
4.5%
(1.8–11.0%)
 
Rectal CT and GC n = 9
10.7%
(5.7–19.1%)
  n = 5
6.2%
(2.7–13.6%)
 
Pharyngeal CT n = 8
9.5%
(4.9–17.7%)
  n = 1
7.9%
(3.9–15.4%)
 
Pharyngeal GC n = 15
17.9%
(11.1–27.4%)
  n = 21
25.9%
(17.6–36.4%)
n = 1
1.2%
(0.2–6.5%)
Pharyngeal CT and GC n = 1
1.2%
(0.2–7.4%)
  n = 1
1.2%
(0.2–6.7%)
 
  1. aSubtotals do not add to 100% as individual participants may have had multiple pathogens and/or anatomic sites of infection
  2. bFive subjects enrolled in the control arm and eight participants in the EPT arm diagnosed with symptomatic disease subsequently tested negative for GC/CT infection by TMA
  3. cOnly cases of infection with the same organism in the same anatomic site at follow-up reported
\